Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial.
Lancet
; 374(9707): 2055-2063, 2009 Dec 19.
Article
in En
| MEDLINE
| ID: mdl-20004966
Full text:
1
Database:
MEDLINE
Main subject:
Tamoxifen
/
Breast Neoplasms
/
Adenocarcinoma
/
Antineoplastic Agents, Hormonal
/
Lymph Nodes
Type of study:
Clinical_trials
/
Prognostic_studies
Language:
En
Journal:
Lancet
Year:
2009
Type:
Article